新股消息 | 勤浩医药二次递表港交所

智通财经
Aug 08
【新股消息 | 勤浩医药二次递表港交所】智通财经APP获悉,据港交所8月7日披露,勤浩医药(苏州)股份有限公司(简称:勤浩医药)第二次向港交所主板提交上市申请书,华泰国际为其独家保荐人。勤浩医药曾于2026年1月首次递表,7月招股书正式失效。招股书显示,勤浩医药是一家成立于2014年的生物制药公司,拥有围绕RAS信号通路及合成致死机制打造的、具有差异化且自主开发创新候选药物管线。该公司专注于开发肿瘤学领域的潜在同类最佳靶向疗法,公司管线包括八款候选药物。其中,核心产品GH21是一种潜在同类最佳的变构SHP2抑制剂,目前处于2期临床试验阶段。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10